H. Lundbeck A/S
HLUN-A
Helyezés a részvények között
#3070
H. Lundbeck A/S engages in the research, development, manufacturing, and... H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Részvényárfolyam
$7.07
Piaci kapitalizáció
$5.91B
Változás (1 nap)
-4.56%
Változás (1 év)
28.57%
Ország
DK
Kereskedés H. Lundbeck A/S (HLUN-A)
Kategória
Healthcare
H. Lundbeck A/S (HLUN-A) nyeresége
Nyereség ekkor: Jun 2026 TTM: $852.45M
H. Lundbeck A/S legfrissebb pénzügyi jelentései szerint a vállalat jelenlegi nyeresége $852.45M. 2024 évben a vállalat $518.88M nyereséget ért el, növekedés a 2023 év nyereségéhez, amely $443.15M volt. Az ezen az oldalon megjelenített nyereség a kamatok és adók előtti eredmény, azaz EBIT.
H. Lundbeck A/S nyereségtörténete 2004 és 2026 között
Nyereség az év végén
| Év | Nyereség | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $852.45M | 20.95% |
| 2025 | $704.82M | 35.83% |
| 2024 | $518.88M | 17.09% |
| 2023 | $443.15M | 24.45% |
| 2022 | $356.09M | 47.28% |
| 2021 | $241.78M | -22.72% |
| 2020 | $312.87M | -40.11% |
| 2019 | $522.42M | -35.68% |
| 2018 | $812.27M | 17.85% |
| 2017 | $689.25M | 125.15% |
| 2016 | $306.13M | -129.99% |
| 2015 | $-1.02B | 11,109.02% |
| 2014 | $-9.11M | -103.36% |
| 2013 | $271.44M | -2.98% |
| 2012 | $279.77M | -51.28% |
| 2011 | $574.21M | -2.65% |
| 2010 | $589.86M | 14.59% |
| 2009 | $514.77M | 29.72% |
| 2008 | $396.85M | -21.21% |
| 2007 | $503.66M | 74.80% |
| 2006 | $288.14M | -19.31% |
| 2005 | $357.09M | -22.52% |
| 2004 | $460.87M | 0.00% |
Hasonló cégek vagy versenytársak nyeresége
| Vállalat | Nyereség | Nyereségkülönbség | Ország |
|---|---|---|---|
| $1.35B | 58.35% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| $26.37M | -96.91% |
US
|
|
| - | - |
IT
|
